SB-431542
Appearance
Identifiers | |
---|---|
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C22H16N4O3 | |
Molar mass | 384.4 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7.[1] (It is NOT an ALK inhibitor).
In-vitro studies
It also suppressed the TGF-beta-induced proliferation of osteosarcoma cells in humans.[1]
As of January 2016[update] There are no clinical trials registered for SB-431542 for cancer or any other indication.[2]
In vitro use
The treatment with SB431542 is a robust, clinically applicable, and efficient system for generating mesenchymal stem/stromal cells (MSCs) from human iPSCs.[3]
References
- ^ a b Laping, NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA (2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology. 62 (1): 58–64. doi:10.1124/mol.62.1.58. PMID 12065755.
- ^ Search results for SB-431542
- ^ Chen Y S, Pelekanos R A., Ellis R L., et al and Nicholas M. Fisk (2012). Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/Stromal Cells Stem Cells Trans Med., 1(2), 83-95 doi:10.5966/sctm.2011-0022